Eli Lilly & CO Form 4 insider transactions

Gabrielle Sulzberger, a director at Eli Lilly, acquired shares of common stock through a deferral plan, increasing her holdings.

Director Juan R. Luciano of Eli Lilly & Co. acquired shares through a deferral plan, increasing his holdings.

Director William G. Kaelin Jr. acquired shares of Eli Lilly & Co. common stock on November 18, 2024.

Director Kimberly H. Johnson acquired shares of Eli Lilly stock through a deferral plan, increasing her holdings.

Director Jamere Jackson acquired 302.53 shares of Eli Lilly & Co. common stock at a price of $727.2 per share on November 18, 2024.

Mary Lynne Hedley, a director at Eli Lilly & Co, acquired shares of common stock through a deferral plan and a trust.

Director J. Erik Fyrwald of Eli Lilly & Co. acquired shares of common stock on November 18, 2024.

Director Katherine Baicker acquired shares of Eli Lilly & Co. common stock in a recent transaction.

Director Ralph Alvarez of Eli Lilly & Co. acquired shares of common stock through a deferral plan, increasing his holdings.

Donald A. Zakrowski, SVP, Finance, & CAO of Eli Lilly, sold 900 shares of common stock at $803.38 per share on November 8, 2024, under a pre-arranged 10b5-1 trading plan.

Eli Lilly's EVP & CFO, Lucas Montarce, executed transactions involving company stock, including the vesting of restricted stock units and the subsequent sale of shares to cover taxes.

Executive Vice President Edgardo Hernandez of Eli Lilly & Co. reported the acquisition and disposal of company stock and restricted stock units on November 1, 2024.

Executive Vice President of Human Resources and Diversity at Eli Lilly, Eric Dozier, reports the acquisition and disposal of company stock and restricted stock units.

Eli Lilly's Executive Vice President and President of Lilly Oncology, Jacob Van Naarden, transferred 4,302 shares of common stock to his spouse.

Gabrielle Sulzberger, a director at Eli Lilly & Co, acquired 11 shares of common stock through a deferral plan.

Director Juan R. Luciano acquired 16 shares of Eli Lilly common stock at $906.13 per share through a deferral plan.

Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 11 shares of common stock through a deferral plan.

Mary Lynne Hedley, a director at Eli Lilly, acquired 11 shares of common stock through a deferral plan.

Director Ralph Alvarez acquired 13 shares of Eli Lilly common stock through a deferral plan, at a price of $906.13 per share.

Gabrielle Sulzberger, a director at Eli Lilly, acquired 11 shares of common stock through a deferral plan.

Director Juan R. Luciano acquired 16 shares of Eli Lilly common stock through a deferral plan, at a price of $923.54 per share.

Director Kimberly H. Johnson acquired 10 shares of Eli Lilly common stock through a deferral plan, as reported in a recent SEC filing.

Mary Lynne Hedley, a director at Eli Lilly, acquired 11 shares of common stock through a deferral plan, with the shares to be settled after her separation from service.

Eli Lilly director Ralph Alvarez acquired 13 shares of common stock through a deferral plan, increasing his direct holdings to 54,254 shares.

Eli Lilly executive Daniel Skovronsky reported the transfer of company shares through gifts, including to a family trust and his spouse.

Lilly Endowment Inc. sold a total of 23,084 shares of Eli Lilly & Co common stock in multiple transactions on September 3, 2024.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., has sold a portion of its holdings in multiple transactions on August 27, 2024.

Donald A. Zakrowski, SVP, Finance, & CAO of Eli Lilly, sold 750 shares of common stock at $950 per share on August 26, 2024, under a pre-arranged 10b5-1 trading plan.

Lilly Endowment Inc. sold 3,196 shares of Eli Lilly & Co. common stock in multiple transactions on August 22, 2024.

Eli Lilly CEO David Ricks reported a transfer of shares and updated his beneficial ownership in a recent SEC filing.